- Home
- GDEN vs NUVB Comparison
GDEN vs NUVB Comparison
Compare GDEN & NUVB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GDEN
- NUVB
- Stock Information
- Founded
- GDEN 1998
- NUVB 2018
- Country
- GDEN United States
- NUVB United States
- Employees
- GDEN N/A
- NUVB N/A
- Industry
- GDEN Services-Misc. Amusement & Recreation
- NUVB Biotechnology: Pharmaceutical Preparations
- Sector
- GDEN Consumer Discretionary
- NUVB Health Care
- Exchange
- GDEN Nasdaq
- NUVB Nasdaq
- Market Cap
- GDEN 888.7M
- NUVB 774.1M
- IPO Year
- GDEN 1999
- NUVB N/A
- Fundamental
- Price
- GDEN $32.45
- NUVB $2.21
- Analyst Decision
- GDEN Strong Buy
- NUVB Strong Buy
- Analyst Count
- GDEN 7
- NUVB 6
- Target Price
- GDEN $36.57
- NUVB $7.67
- AVG Volume (30 Days)
- GDEN 136.1K
- NUVB 1.6M
- Earning Date
- GDEN 02-27-2025
- NUVB 03-03-2025
- Dividend Yield
- GDEN 3.08%
- NUVB N/A
- EPS Growth
- GDEN N/A
- NUVB N/A
- EPS
- GDEN 1.27
- NUVB N/A
- Revenue
- GDEN $733,305,000.00
- NUVB $2,162,000.00
- Revenue This Year
- GDEN N/A
- NUVB N/A
- Revenue Next Year
- GDEN $1.92
- NUVB $374.06
- P/E Ratio
- GDEN $25.61
- NUVB N/A
- Revenue Growth
- GDEN N/A
- NUVB N/A
- 52 Week Low
- GDEN $27.42
- NUVB $1.67
- 52 Week High
- GDEN $37.30
- NUVB $4.16
- Technical
- Relative Strength Index (RSI)
- GDEN 45.29
- NUVB 37.58
- Support Level
- GDEN $32.20
- NUVB $2.16
- Resistance Level
- GDEN $35.49
- NUVB $2.38
- Average True Range (ATR)
- GDEN 0.92
- NUVB 0.12
- MACD
- GDEN -0.03
- NUVB 0.00
- Stochastic Oscillator
- GDEN 15.32
- NUVB 16.13
About GDEN Golden Entertainment Inc.
Golden Entertainment Inc is a U.S. based company that focuses on distributed gaming, casino, and resort operations. Its reportable segments are Nevada Casino Resorts, Nevada Locals Casinos, Nevada Taverns, and Distributed Gaming. The majority of the revenue for the company is generated from its Nevada Casino Resorts segment which is comprised of destination casino resort properties offering a variety of food and beverage outlets, entertainment venues, and other amenities.
About NUVB Nuvation Bio Inc.
Nuvation Bio Inc is a biopharmaceutical company tackling unmet needs in oncology by developing differentiated and novel therapeutic candidates. The company's clinical-stage product candidate is NUV-868, a BD2-selective oral small molecule BET inhibitor. NUV-868 inhibits the protein BRD4, a key member of the BET family that epigenetically regulates a number of important proteins that control tumor growth and differentiation, including oncogenes such as c-myc. Notably, BET proteins have critical biological functions and are found to be altered in many human cancers. It is also developing its proprietary, small molecule Drug-Drug Conjugate (DDC) platform, a novel therapeutic approach within the drug-conjugate class of anti-cancer therapies with parallels to Antibody-Drug Conjugates (ADCs).